The Effects of Bromelain Supplement in Patients with Diabetic Foot Ulcers

Investigating the Effectiveness of the Supplement Containing Enteric-coated Bromelain (Anaheal 1200 GDU) in Healing Wounds, Pain, and Inflammation in Patients Over 18 Years Old with Diabetic Foot Ulcers Compared to Placebo

This study will be conducted on people over 18 with diabetic foot ulcers.. The first group will receive the standard treatment along with bromelain supplement and the second group will receive the standard treatment and placebo. The informed consent form prepared in advance will also be provided to the patients so that they are fully familiar with the study process. Wound surface area, rate of pain, rate of inflammatory factors (ESR and CRP) will be assessed at baseline and every two weeks.

Inclusion Criteria:

• Patients over 18 years old
• Patients diagnosed with diabetic foot ulcers of category 0, 1 and 2 according to the Wagner criteria
• Patients aware of the study process for monitoring after filling out the informed consent form

Exclusion Criteria:

• People who are allergic to pineapple, celery, carrot and fennel
• Pregnant and lactating women
• Severe kidney failure (GFR<30)
• Severe liver failure (Child Pugh B, C)
• Patients with hemophilia
• People taking anticoagulant drugs, anti-platelet and thrombolytic
• Patients with irregular heartbeat and tachycardia
• Patients with asthma